Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Wave Life Sciences is positioned to potentially transform human health through their innovative RNA medicines platform, PRISM, which combines multiple modalities, chemistry innovation, and deep insights into human genetics. Positive mid-2026 FDA accelerated approval feedback for their potential blockbuster drug, WVE-006, and the data expected at EASL in second quarter of 2026 could validate its regulatory strategy. The company's high potential for success is reflected in their strong pipeline and partnerships with other major biotech companies.

Bears say

Wave Life Sciences is facing strong competitive pressures, as new biomarker data from Sanofi establishes a higher reference point for total AAT levels and functional AAT trough in the lung disease segment. This, combined with a regulatory lead held by a competitor and potential uncertainties around the FDA's biomarker composite and threshold, raises questions about the company's commercial differentiation and its ability to secure approval and market share. There is also a high clinical risk associated with the early-stage nature of the company's pipeline, as well as other standard biotech industry risks.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences Inc (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences Inc (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.